Neutropenia is a hematological disorder defined as a reduction in the absolute number of neutrophils in the blood. The most common causes of neutropenia are those that are acquired, including viral ...

Predictive models to identify low-risk febrile neutropenia (FN) have been developed with heterogeneous samples, which included stable and unstable patients, solid tumours, acute leukaemia and bone ...

Neutropenia represents an abnormally low level of neutrophils in the blood. This condition can be graded as mild, moderate, and severe, corresponding respectively to absolute neutrophil count values ...

Close monitoring via weekly complete blood counts (CBCs) for the first 2 months is essential to mitigate risks, according to Zeidan. Supportive care such as platelet transfusions or growth factors may ...

Among patients with pancreatic cancer being treated with modified FOLFIRINOX, those who develop severe neutropenia have significantly longer median overall survival, as well as longer time to ...

The American Society of Clinical Oncology (ASCO) has bulked up its advice to clinicians about managing patients who undergo chemotherapy. The organization has issued a new guideline on how and when to ...

In a series of interviews with MD Magazine, Yoav Golan, MD, MS, FIDSA, discussed some health risks for patients with acute myeloid leukemia who are experiencing neutropenia. In a series of interviews ...

The subjects of this study were identified from among the patients participating in a nationwide survey of oral fluoropyrimidine derivative S-1 (TS-1 ®; Taiho Pharmaceutical Co. Ltd, Tokyo, Japan) in ...

When you get chemotherapy for breast cancer, you’ll very likely run low on white blood cells called neutrophils. Doctors call this neutropenia. It’s a normal part of going through chemo. With ...

Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer We identified 8,745 patients age ...

On June 27, 2024, X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) held a webinar to provide an interim update for the ongoing Phase 2 clinical trial of mavorixafor in patients with chronic neutropenia (CN).

Between January 2001 and December 2002, LACHIS provided 134 courses of long-term home antimicrobial therapy for osteomyelitis. No cases of neutropenia were reported for the 121 courses of ...